Recent developments in the pharmacotherapy of mood disorders

Journal of Consulting and Clinical Psychology

Volumn 64, Issue 4, 1996, Pages 646-659

  Thase, Michael E ^a,b   Kupfer, David J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BROFAROMINE; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM CARBONATE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MOOD; NAUSEA; NERVOUSNESS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; TREMOR;

EID: 0029833027     PISSN: 0022006X     EISSN: None     Source Type: Journal    
DOI: 10.1037/0022-006X.64.4.646     Document Type: Review

References (206)

1. Aagaard, J., Vestergaard, P., & Maarbjerg, K. (1988). Adherence to lithium prophylaxis: II. Multivariate analysis of clinical, social, and psychosocial predictors of nonadherence. Pharmacopsychiatry, 21, 166-170.
2. Agosti, V., Stewart, J. W., Quitkin, F. M., & Ocepek-Welikson, K. (1993). How symptomatic do depressed patients remain after benefiting from medication treatment? Comprehensive Psychiatry, 34, 182-186.
3. Aguglia, E., Casacchia, M., Cassano, G. B., Faravelli, C., Ferrari, G., Giordano, P., Pancheri, P., Ravizza, L., Trabucchi, M., Bolino, F., Scarpato, A., Berardi, D., Provenzano, G., Brugnoli, R., & Rozzini, R. (1993). Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. International Clinical Psychopharmacology, 8, 197-202.
4. Akiskal, H. S. (1994). Dysthymia: Clinical and external validity. Acta Psychiatrica Scandinavica, 89, 19-23.
5. Altamura, A., Montgomery, S., & Wernicke, J. (1988). The evidence for 20 mg a day of fluoxetine as the optimal in the treatment of depression. British Journal of Psychiatry, 153 (Suppl. 3), 109-112.
6. American Psychiatric Association. (1993). Practice guideline for major depressive disorder in adults. American Journal of Psychiatry, 150 (Suppl. 4), 1-26.
7. American Psychiatric Association. (1994). Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry, 151 (12, Suppl.), 1-35.
8. Armitage, R., Rush, A. J., Trivedi, M., Cain, J., & Roffwarg, H. P. (1994). The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology, 10, 123-127.
9. Ascher, J. A., Cole, J. O., Colin, J.-N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., Richelson, E., & Sulser, F. (1995). Bupropion: A review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395-401.
10. Austin, M. P. V., Souza, F. G. M., & Goodwin, G. M. (1991). Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. British Journal of Psychiatry, 159, 510-514.
11. Baldessarini, R. J. (1983). Biomedical aspects of depression and its treatment. Washington, DC: American Psychiatric Press.
12. Barden, N., Reul, J. M. H. M., & Holsboer, F. (1995). Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences, 18, 6-11.
13. Bauer, M. S., Calabrese, J., Dunner, D. L., Post, R., Whybrow, P. C., Gyulai, L., Tay, L. K., Younkin, S. R., Bynum, D., Lavori, P., & Price, R. A. (1994). Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. American Journal of Psychiatry, 151, 506-515.
14. Beasley, C. M., Dornseif, B. E., Bosomworth, J. C., Saylor, M. E., Rampey, A. H., & Heiligenstein, J. H. (1991). Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. British Medical Journal, 303, 685-692.
15. Beasley, C. M., Jr., Masica, D. N., Heiligenstein, J. H., Wheadon, D. E., & Zerbe, R. L. (1993). Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and pre-clinical findings. Journal of Clinical Psychopharmacology, 13, 312-320.
16. Beasley, C. M., Sayler, M. E., Cunningham, G. E., Weiss, A. M., & Masica, D. N. (1990). Fluoxetine in tricyclic refractory major depressive disorder. Journal of Affective Disorders, 20, 193-200.
17. Belsher, G., & Costello, C. G. (1988). Relapse after recovery from unipolar depression: A critical review. Psychological Bulletin, 104, 84-96.
18. Black, D. W., Winokur, G.,& Nasrallah, H. (1987). Treatment of mania: A naturalistic study of ECT versus lithium in 438 patients. Journal of Clinical Psychiatry, 48, 132-139.
19. Bolden-Watson, C., & Richelson, E. (1993). Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences, 52, 1023-1029.
20. Bowden, C. L., Brugger, A. M., Swann, A. C., Calabrese, J. R., Janicak, P. G., Petty, F., Dilsaver, S. C., Davis, J. M., Rush, A. J., Small, J. G., Garza-Trevino, E. S., Risen, S. C., Goodnick, P. J., Morris, D. D., & the Depakote Mania Study Group. (1994). Efficacy of divalproex vs. lithium and placebo in the treatment of mania. Journal of the American Medical Association, 271, 918-924.
21. Bowers, W. A. (1990). Treatment of depressed inpatients. Cognitive therapy plus medication, relaxation plus medication, and medication alone. British Journal of Psychiatry, 156, 73-78.
22. Breggin, P. R., & Breggin, G. R. (1994). Talking back to Prozac. New York: St. Martin's Press.
23. Brown, W. A., & Harrison, W. (1995). Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Journal of Clinical Psychiatry, 56, 30-34.
24. Burke, M. J., Silkey, B., & Preskorn, S. H. (1994). Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. Journal of Clinical Psychiatry, 55(Suppl. A), 42-52.
25. Calabrese, J. R., & Delucchi, G. A. (1990). Spectrum of efficacy of valproate in 55 patients with rapid cycling bipolar disorder. American Journal of Psychiatry, 147, 431-434.
26. Cesura, A. M., & Pletscher, A. (1992). The new generation of monoamine oxidase inhibitors. Progress in Drug Research, 38, 171-297.
27. Chouinard, G. (1988). The use of benzodiazepines in the treatment of manic depressive illness. Journal of Clinical Psychiatry, 49( Suppl.), 15-19.
28. Claghorn, J. L., & Feighner, J. P. (1993). A double-blind comparison of paroxetine with imipramine in the long-term-treatment of depression. Journal of Clinical Psychopharmacology, 13(Suppl 6), 23-27.
29. Clarke, T. B., Coffey, E. C., Hoffman, G. W., & Weiner, R. D. (1989). Continuation therapy for depression using outpatient BCT. Convulsive Therapy, 5, 330-337.
30. Clerc, G. E., Ruimy, P., & Verdeau-Pilles, J. (1994). A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology, 9, 139-143.
31. Cochran, S. D. (1984). Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. Journal of Consulting and Clinical Psychology, 52, 873-878.
32. Cohn, J. B., Collins, G., Ashbrook, E., & Wernicke, J. F. (1989). A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. International Clinical Psychopharmacology, 4, 313-322.
33. Coryell, W., Endicott, J., & Keller, M. (1992). Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Archives of General Psychiatry, 49, 126-131.
34. Coryell, W., Scheftner, W., Keller, M., Edicott, J., Maser, J., & Klerman, G. L. (1993). The enduring psychosocial consequences of mania and depression. American Journal of Psychiatry, 150, 720-727.
35. Coxhead, N., Silverstone, T., & Cookson, J. (1992). Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatrica Scandinavica, 85, 114-118.
36. Danish University Antidepressant Group. (1986). Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study. Psychopharmacology, 90, 131-138.
37. Danish University Antidepressant Group. (1990). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289-299.
38. Davidson, J. (1989). Seizures and bupropion: A review. Journal of Clinical Psychiatry, 50, 256-261.
39. DeJong, R., Treiber, R., & Henrich, G. (1986). Effectiveness of two psychological treatments for inpatients with severe and chronic depressions. Cognitive Therapy Research, 10, 645-663.
40. Depression Guideline Panel. (1993 ). (Clinical Practice Guideline No. 5.) Depression in primary care: Vol. 2. Treatment of major depression (AHCPR Publication no. 93-0551). Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research.
41. De Vane, C. L. (1992). Pharmacokinetics of the selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry, 53, 13-20.
42. Dobson, K. (1989), A meta-analysis of the efficacy of cognitive therapy of depression. Journal of Consulting and Clinical Psychology, 57, 414-419.
43. Doogan, D. P., & Caillard, V. (1992). Sertraline in the prevention of depression. British Journal of Psychiatry, 160, 217-222.
44. Dreifuss, F. E., Santilli, N., Langer, D. H., Sweeney, K. P., Moline, K. A., & Menander, K. B. (1987). Valproic acid hepatic fatalities: A retrospective review. Neurology, 37, 379-385.
45. Duboff, E. A. (1993). Long-term treatment of major depressive disorder with paroxetine. Journal of Clinical Psychopharmacology, 13(Suppl. 6), 28S-33S.
46. Dubovsky, S. L., Franks, R. D., Allen, S., & Murphy, J. (1986). Calcium antagonists in mania: A double-blind study of verapamil. Psychiatry Research, 18, 309-320.
47. Dubovsky, S. L., Murphy, J., Thomas, M., & Rademacher, J. (1992). Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. American Journal of Psychiatry, 149, 118-120.
48. Dunner, D. L., & Dunbar, G. C. (1992). Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53, 21-26.
49. Elkin, I., Shea, M. T., Watkins, J. T., Imber, S. D., Sotsky, S. M., Collins, J. F., Glass, D. R., Pilkosis, P. A., Leber, W. R., Docherty, J. P., Fiester, S. J., & Parloff, M. B. (1989). National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Archives of General Psychiatry, 46, 971-982.
50. Evans, M. D., Hollon, S. D., & DeRubeis, R. J. (1992). Differential relapse following cognitive therapy and pharmacotherapy for depression. Archives of General Psychiatry, 49, 802-809.
51. Fabre, L. F., Abuzzahab, F. S., Amin, M., Claghorn, J. L., Mendels, J., Petrie, W. M., Dube, S., & Small, J. G. (1995). Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biological Psychiatry, 38, 592-602.
52. Fava, G. A. (1994). Do antidepressants and antianxiety drugs increase chronicity in affective disorders? Psychotherapy and Psychosomatics, 61, 125-131.
53. Fava, M., & Rosenbaum, J. (1991). Suicidality and fluoxetine: Is there a relationship? Journal of Clinical Psychiatry, 52, 108-111.
54. Fava, M., Rosenbaum, J. F., McGrath, P. J., Stewart, J. W., Amsterdam, J. D., & Quitkin, F. M. (1994). Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. American Journal of Psychiatry, 151, 1372-1374.
55. Fawcett, J., Epstein, P., Fiester, S., Elkin, I., & Autry, J. (1987). Clinical management-imipramine/placebo administration manual. Psychopharmacology Bulletin, 23, 309-324.
56. Fawcett, J., Marcus, R. N., Anton, S. F., O'Brien, K., & Schwiderski, U. (1995 ). Response of anxiety and agitation symptoms daring nefazodone treatment of major depression. Journal of Clinical Psychiatry, 56 (Suppl.6), 37-42.
57. Ferris, R. M., & Cooper, B. R. (1993). Mechanism of antidepressant activity of bupropion. Journal of Clinical Psychiatry, 11, 2-14.
58. Fisher, S., & Greenberg, R. (1993). How sound is the double-blind desire for evaluating drugs? Journal of Nervous and Mental Disease, 181, 345-350.
59. Fontaine, R., Ontiveros, A., Elie, R., & Vezina, M. (1991). Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biological Psychiatry, 29, 946.
60. Frank, E., Karp, J. F., & Rush, A. J. (1993). Efficacy of treatments for major depression. Psychopharmacology Bulletin, 29, 457-475.
61. Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C., Jarrett, D. B., Mallinger, A. G., Thase, M. E., McEachran, A. B., & Grochocinski, V. J. (1990). Three year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093-1099.
62. Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C., Mallinger, A. G., Thase, M. E., McEachran, A. B., Grochocinski, V. J. (1993). Comparison of full dose versus half dose pharmacotherapy in the maintenance treatment of recurrent depression. Journal of Affective Disorders, 27, 139-145.
63. Frank, E., Kupfer, D. J., Wagner, E. F., McEachran, A., & Cornes, C. (1991). Efficacy of interpersonal psychotherapy as a maintenance treatment for recurrent depression: Contributing factors. Archives of General Psychiatry, 48, 1053-1059-948.
64. Frank, E., Prien, R. F., Jarrett, D. B., Keller, M. B., Kupfer, D. J., Lavori, P., Rush, A. J., & Weissman, M. M. (1991). Conceptualization and rationale to consensus definitions of terms in major depressive disorder: Response, remission, recovery, relapse, and recurrence. Archives of General Psychiatry, 48, 851-855.
65. Freeman, T. W., Clothier, J. L., Pazzaglia, P., Lesem, M. D., & Swann, A. C. (1992). A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry, 149, 108-111.
66. Gardner, E. A., & Johnston, J. A. (1985). Burpropion-an antidepressant without sexual pathophysiological action. Journal of Clinical Psychopharmacology, 5, 24-29.
67. Garza-Trevino, E. S., Overall, J. E., & Hollister, L. E. (1992). Verapamil versus lithium in acute mania. American Journal of Psychiatry, 149, 121-122.
68. Gelenberg, A. K., Kane, J. M., & Keller, M. D. (1989). Comparison of standard and low levels of lithium for maintenance treatment of bipolar disorder. New England Journal of Medicine, 321, 1489-1493.
69. 3 to potentiate tricyclic antidepressant response. Journal of Affective Disorder, 13, 267-272.
70. Goodnick, P. J., & Extein, I. L. (1989). Bupropion and fluoxetine in depressive subtypes. Annals of Clinical Psychiatry, 1, 119-122.
71. Goodwin, F. K., Prange, A. J., Post, R. M., Muscettola, F., & Lipton, M. A. (1982). Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. American Journal of Psychiatry, 139, 34-38.
72. Guelfi, J. D., White, C., Hackett, D., Guichoux, J. Y., Magni, G. (1995). Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56, 450-458.
73. Harrison, W. M., & Stewart, J. W. (1993). Pharmacotherapy of dysthymia. Psychiatric Annals, 23, 638-648.
74. Hart, R. G., & Easton, J. D. (1982). Carbamazepine and hematological monitoring. Annals of Neurology, 11, 309-312.
75. Haykal, R. F., & Akiskal, H. S. (1990). Bupropion as a promising approach to rapid cycling bipolar II patients. Journal of Clinical Psychiatry, 51, 450-455.
76. Heiligenstein, J. H., Faries, D. E., Rush, A. J., Andersen, J. S., Pande, A. C., Roffwarg, H. P., Dunner, D., Gillin, J. C., James, S. P., Lahmeyer, H., Zajecka, J., Tollefson, G. D., & Gardner, D. M. (1994). Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Research, 52, 327-339.
77. Hellerstein, D. J., Yanowitch, P., Rosenthal, J., Samstag, L. W., Maurer, M., Kasch, K., Burrows, L., Poster M., Cantillon, M., & Winston, A. (1993). A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. American Journal of Psychiatry, 150, 1169-1175.
78. Henry, J. A. (1993). Debits and credits in the management of depression. British Journal of Psychiatry, 163(Suppl. 20), 33-39.
79. Himmelhoch, J. M., Thase, M. E., Mallinger, A. G., &. Houck, P. (1991). Tranylcypromine versus imipramine ia anergic bipolar depression. American Journal of Psychiatry, 148, 910-916.
80. Hollon, S. D., DeRubeis, R. J., Evans, M. D., Wiemer, M. J., Garvey, M. J., Grove, W. M., & Tuason, V. B. (1992). Cognitive-therapy and pharmacotherapy for depression: Singly and in combination. Archives of General Psychiatry, 49, 774-781.
81. Howland, R. H. (1991). Pharmacotherapy of dysthymia: A review. Journal of Clinical Psychopharmacology, 11, 83-92.
82. Janicak, P. G., Newman, R. J., & Davis, J. M. (1992). Advances in the treatment of mania and related disorders: A reappraisal. Psychiatric Annals, 22, 92-103.
83. Joffe, R. T., & Singer, W. (1990). A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Research, 32, 241-251.
84. Joffe, R. T., Singer, W., Levitt, A. J., & MacDonald, C. (1993). A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry 50, 387-393.
85. Kapur S., Mieczkowski, T., & Mann, J. J. (1992). Antidepressant medications and the relative risk of suicide attempt and suicide. Journal of the American Medical Association, 268, 3441-3445.
86. Katon, W., & Schulberg, H. (1992). Epidemiology of depression in primary care: General Hospital Psychiatry, 14, 237-242.
87. Katon, W., Von Korff, M., Lin, E., Bush, T., & Ormel, J. (1992). Adequacy and duration of antidepressant treatment in primary care. Medical Care, 30, 67-76.
88. Keller, M. B., Harrison, W., Fawcett, J., Gelenberg, A., Hirschfeld, R. M. A., Klein, D., Kocsis, J. H., McCullough, J. P., Rush, A. J., Schatzberg, A., & Thase, M. E. (1995). Treatment of chronic depression with sertraline or imipramine. Preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacology Bulletin, 31, 205-212.
89. Keller, M. B., Lavori, P. W., Kane, J. M., Gelenberg, A. J., Rosenbaum, J. F., Walzer, E. A., & Baker, L. A. (1992). Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Archives of General Psychiatry, 49, 371-376.
90. Keller, M. B., Lavori, P. W., Mueller, T. I., Endicott, J., Coryell, W., Hirschfeld, R. M. A., & Shea, T. (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Archives of General Psychiatry, 49, 809-816.
91. Keller, M. B., & Shapiro, R. W. (1982). "Double-depression": Super-imposition of acute depressive episodes on chronic depressive disorders. American Journal of Psychiatry, 139, 438-442.
92. Kendall, P. C., Kipnis, D., & Otto-Salaj, L. (1992). When clients don't progress: Influences on and explanations for lack of therapeutic progress. Cognitive Therapy and Research, 16, 269-281.
93. Ketter, T. A., Pazzaglia, P. J., & Post, R. M. (1992). Synergy of carbamazepine and valproic acid in affective illness: Case report and review of the literature. Journal of Clinical Psychopharmacology, 12, 276-281.
94. Kiev, A., Masco, H., Wenger, T. L., Johnston, A., Batey, S. R., & Holloman, L. C. (1994). The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Annals of Clinical Psychiatry, 6, 107-115.
95. Klein, D. F., & Ross, D. C. (1993). Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program general effectiveness report. Neuropsychopharmacology, 8, 241-251.
96. Klerman, G. L. (1990). The psychiatric patient's right to effective treatment: Implications of Osheroff v. Chestnut Lodge. Journal of Psychiatry, 147, 409-418.
97. Kocsis, J. H., Frances, A. J., Voss, C., Mann, J. J., Mason, B. J., & Sweeney, J. (1988). Imipramine treatment for chronic depression. Archives of General Psychiatry, 45, 253-257.
98. Kukopulos, A., Reginaldi, D., Laddomada, P., Floris, G., Serra, G., & Tondo, L. (1980). Course of manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry and Neuropsychopharmacology, 13, 156-167.
99. Kupfer, D. J. (1991). Long-term treatment of depression. Journal of Clinical Psychiatry 52, 28-42.
100. Kupfer, D. J., Frank, E., McEachran, A. B., & Grochocinski, V. J. (1990). Delta sleep ratio: A biological correlate of early recurrence in unipolar affective disorder. Archives of General Psychiatry, 47, 110-1105.
101. Kupfer, D. J., Frank, E., Perel, J. M., Cornes, C., Mallinger, A. G., Thase, M. E., McEachran, A. B., & Grochocinski, V. ( 1992). Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry, 49, 769-773.
102. Lecrubier, Y., & Guelfi, J. D. (1990). Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatrica Scandinavica, 360(Suppl.), 18-23.
103. Lennox, R. H., Newhouse, P. A., Creelman, W. L., & Whitaker, T. M. (1992). Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. Journal of Clinical Psychiatry, 52, 47-52.
104. Lerer, B., Moore, N., Meyendorff, E., Cho, S.-R. & Gershon, S. (1987). Carbamazepine versus lithium in mania: A double-blind study. Journal of Clinical Psychiatry, 48, 89-93.
105. Manji, H. K. (1992). G Proteins: Implications for psychiatry. American Journal of Psychiatry, 149, 746-760.
106. Mann, J. J., Aarons, S. F., Wilner, P. J., Keilp, J. G., Sweeney, J. A., Pearlstein, T., Frances, A. J., Kocsis, J. H., & Brown, R. P. (1989). A controlled study of the antidepressant efficacy and side effects of(-)-Deprenyl. A selective monoamine oxidase inhibitor. Archives of General Psychiatry, 46, 45-50.
107. McElroy, S. L., Keck, P. E., Pope, H. G., & Hudson, J. I. (1992). Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines. Journal of Clinical Psychopharmacology, 12, 42S-52S.
108. Meterissian, G. B., & Bradwejn, J. (1989). Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: Was adequate pharmacotherapy provided? Journal of Clinical Psychopharmacology, 9, 334-339.
109. Miller, I. W., Norman, W. H., & Keitner, G. I. (1990). Treatment response of high cognitive dysfunction depressed inpatients. Comprehensive Psychiatry, 30, 62-71.
110. Mintz, J., Mintz, L. I., Arruda, M. J., & Hwang, S. S. (1992). Treatments of depression and the functional capacity to work. Archives of General Psychiatry 49, 761-768.
111. Montgomery, S. A., Dufour, H., Brion, S., Gailledreau, J., Laqueille, X., Ferrey, G., Moron, P., Parant-Lucena, N., Singer, L., Danion, J. M., Neuzen, J. N., & Pierredon, M. A. (1988). The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry, 153(Suppl.3), 69-76.
112. Mukherjee, S., Sackeim, H. A., & Schnur, D. B. (1994). Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. American Journal of Psychiatry, 151, 169-176.
113. Muñoz, R., Hollon, S., McGrath, E., Rehm, K., & VandenBos, G. (1994). On the AHCPR Depression in Primary Care Guidelines. Further consideration for practitioners. American Psychologist, 49, 42-61.
114. Myers, E., & Branthwaithe, A. (1992). Out-patient compliance with antidepressant medication. British Journal of Psychiatry, 160, 83-86.
115. Narrow, W. E., Regier, D. A., Rae, D. S., Manderscheid, R. W., Locke, B. Z. (1993). Use of services by persons with menial and addictive disorders. Findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Archives of General Psychiatry, 50, 95-107.
116. Nelson, J. C. (1994). Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatric Annals, 24, 628-631.
117. Nelson, J. C., Mazure, C. M., Boners, M. B., & Jatlow, P. (1991). A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry, 48, 303-307.
118. Nierenberg, A. A., Feighner J. P., Rudolph, R., Cole, J. O., & Sullivan, J. (1994). Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 14, 419-423.
119. Nierenberg, A. A., & White, K. (1990). What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacology Bulletin, 26, 429-460.
120. Olfson, M., & Klerman, G. L. (1993). Trends in the prescription of antidepressants by office-based psychiatrists. American Journal of Psychiatry, 150, 571-577.
121. Pande, A., & Sayler, M. (1993). Severity of depression and response to fluoxetine. International Clinical Psychopharmacology, 8, 243-245.
122. Parker, G., Hadzi-Pavlovic, D., & Boyce, P. (1989). Endogenous depression as a construct: A quantitative analysis of the literature and a study of clinician judgements. Australian and New Zealand Journal of Psychiatry, 23, 357-368.
123. Perry, P. J., Zeilmann, C., & Arndt, S. (1994). Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. Journal of Clinical Psychopharmacology, 14, 230-240.
124. Persons, J. B., Thase, M. E., & Crits-Christoph, P. (1996). The role of psychotherapy in the treatment of depression. Archives of General Psychiatry, 53, 283-290.
125. Peselow, E. D., Filippi, A. M., Goodnick, P., Barouche, F., & Fieve, R. R. (1989). The short- and long-term efficacy of paroxetine HCI: B. Data from a double-blind crossover study and from a year long trial vs. imipramine and placebo. Psychopharmacology Bulletin, 25, 272-276.
126. Peselow, E. D., Sanfilipo, M. P., Difiglia, C. & Fieve, R. R. (1992). Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 149, 1324-1334.
127. Placidi, G. F., Lenzi, A., Lazzerini, F. Cassano, B., & Akiskal, H. S. (1986). The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. Journal of Clinical Psychiatry, 47, 490-494.
128. Pope, H. G., Jr., McElroy, S. L., Keck, P. E., & Hudson, J. L. (1991). A placebo-controlled study of valproate in mania. Archives cf General Psychiatry, 48, 62-68.
129. Post, R. M. (1990). Non-lithium treatment for bipolar disorder. Journal of Clinical Psychiatry, 51(Suppl. 8), 9-16.
130. Post, R. M., Leverich, G. &, Altshuler, L., & Mikalauskas, K. (1992). Lithium-discontinuation-induced refractoriness: Preliminary observations. American Journal of Psychiatry, 149, 1727-1729.
131. Potter, W., Rudorfer, M., & Manji, H. (1991). The pharmacologic treatment of depression. New England Journal of Medicine, 325, 633-642.
132. Preskorn, S. H. (1995). Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefezodone, paroxetine, sertraline, and venlafaxine. Journal of Clinical Psychiatry, 56(Suppl. 6), 12-21.
133. Preskorn, S. H., & Burke, M. (1992). Somatic therapy for major depressive disorder: Selection of an antidepressant. Journal of Clinical Psychiatry, 53(Suppl. 9), 5-18.
134. Preskorn, S. H., & Fast, G. A. (1991). Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry, 52, 23-33.
135. Price, L. H., Charney, D. S., Delgado, P. L., & Heninger, G. R. (1989). Lithium treatment and serotonergic function. Neuroendocrine and behavioral responses to intravenous tryptophan in affective disorder. Archives of General Psychiatry, 46, 13-19.
136. Prien, R. F., & Kocsis, J. H. (1995). Long-term treatment of mood disorders. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The fourth generation of progress (pp. 1067-1079). New York: Raven Press.
137. Prien, R. F., & Kupfer, D. J. (1986). Continuation drug therapy for major depressive episodes: How long should it be maintained? American Journal of Psychiatry, 143, 18-23.
138. Prien, R. F., Kupfer, D. J., Mansky, P. A., Small, J. G., Tuason, V. B., Voss, C. B., & Jonson, W. E. (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Archives of General Psychiatry, 41, 1096-1104.
139. Prudic, J., Sackeim, H., & Devanand, D. P. (1990). Medication resistance and clinical response to ECT. Psychiatry Research, 31, 287-296.
140. Pryor, J. C., & Sulser, F. (1991). Evolution of the monoamine hypotheses of depression. In R. Horton & C. Katona (Eds.), Biological aspects of affective disorders (pp. 77-94). New York: Academic Press.
141. Quitkin, F. M., Stewart, J. W., McGrath, P. J., Nunes, E., Ocepek-Welikson, K., Tricamo, E., Rabkin, J. G., Ross, D., & Klein, D. F. (1993). Loss of drug effects during continuation therapy. American Journal of Psychiatry, 150, 562-565.
142. Quitkin, F. M., Stewart, J. W., McGrath, P. J., Tricamo, E., Rabkin, J. G., Ocepek-Welikson, K., Nunes, E., Harrison, W., & Klein, D. F. (1993). Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry, 163, 30-34.
143. Regier, D., Hirschfeld, R., Goodwin, F., Burke, J., Lazar, J., & Judd, L. (1988). The NIMH Depression, Awareness, Recognition, and Treatment Program: Structure, aims and scientific basis. American Journal of Psychiatry, 145, 1351-1357.
144. Regier, D. A., Narrow, W. E., Rae, D. S., Manderscheid, R. W., Locke, B. Z., & Goodwin, F. K. (1993). The de facto U.S. mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50, 85-94.
145. Ribeiro, S. C. M., Tandon, R., Grunhaus, L., & Greden, J. F. (1993). The DST as a predictor of outcome in depression: A meta-analysis. American Journal of Psychiatry, 150, 1618-1629.
146. Robins, L. N., & Kulbok, P. A. (1988). Epidemiologic studies in suicide. Review of psychiatry (Vol. 7, pp. 289-306). Washington, DC: American Psychiatric Press.
147. Roose, S. P. (1992). Modern cardiovascular standards for psychotropic drugs. Psychotropic drugs. Psychopharmacology Bulletin, 28, 35-43.
148. Roose, S. P., Glassman, A. H., Attia, E., & Woodring, S. (1994). Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 151, 1735-1739.
149. Rush, A. J., & Weissenburger, J. E. (1994). Melancholic symptom features and DSM-IV. American Journal of Psychiatry, 151, 489-498.
150. Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M., Thibault, A. B., Toben, M., & Rosenbaum, J. F. (1994). A double-blind trial of bupropion versus desipramine for bipolar depression. Journal of Clinical Psychiatry, 55, 391-393.
151. Sackeim, H., Prudic, J., Devanand, D. P., Decina, P., Kerr, B., & Malitz, S. (1990). The impact of medication resistance and continuation pharmacotherapy on relapse following response to ECT in major depression. Journal of Clinical Psychopharmacology, 10, 96-104.
152. Schatzberg, A. F., & Rothschild, A. J. (1992). Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? American Journal of Psychiatry, 149, 733-745.
153. Schone, W., & Ludwig, M. (1993). A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. Journal of Clinical Psychopharmacology, 13(Suppl.), 34S-39S.
154. Schou, M. (1989). Lithium prophylaxis: Myths and realities. American Journal of Psychiatry, 146, 573-576.
155. Schweizer, E., Rickels, K., Amsterdam, J. D., Fox, I., Puzzuoli, G., & Weise, C. (1990). What constitutes an adequate antidepressant trial for fluoxetine? Journal of Clinical Psychiatry, 57, 8-11.
156. Sclar D. A., Robinson, L. M., Skaer, T. L., Legg, R. F., Nemec, N. L., Galin, R. S., Hughes, T. E., & Buesching, D. P. (1994). Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clinical Therapeutics, 16, 715-730.
157. Scott, J. (1992). Chronic depression: Can cognitive therapy succeed when outer treatments fair? Behavioural Psychotherapy, 20, 25-36.
158. Shapiro, D. R., Quitkin, F. M., & Fleiss, J. L. (1989). Response to maintenance therapy in bipolar illness. Archives of General Psychiatry, 46, 401-405.
159. Shea, M. T., Elkin, I., Imber, S. D., Sotsky, S. M., Watkins, J. T., Collins, J. F., Pilkonis, P. A., Beckham, E., Glass, D. R., Doland, R. T., & Parloff, M. B. (1992). Course of depressive symptoms over follow-up. Archives of General Psychiatry, 49, 782-787.
160. Shrivastava, R. K., Cohn, C., Crowder, J., Davidson, J., Dunner, D., Feighner, J., Kiev, A., & Patrick, R. (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology, 14, 322-329.
161. Simons, A. D., Murphy, G. E., & Levine, J. L. (1986). Cognitive therapy and pharmacotherapy of depression: Sustained improvement over one year. Archives of General Psychiatry, 43, 43-48.
162. Simons, A. D., & Thase, M. E. (1992). Biological markers, treatment outcome, and 1-year follow-up of endogenous depression: Eletroencephalographic sleep studies and response to cognitive therapy. Journal of Consulting and Clinical Psychiatry, 60, 392-401.
163. Small, J. G., Klapper, M. H., Kellams, J. J., Miller, M. J., Milstein, V., Sharpley, P. H., & Small, I. F. (1988). ECT compared with lithium in the management of manic states. Archives of General Psychiatry, 45, 727-732.
164. Small, J. G., Klapper, M. H., Milstein, V., Kellams, J. J., Miller, M. J., Merhenke, J. D., & Small, I. F. (1991). Carbamazepine compared with lithium in the treatment of mania. Archives of General Psychiatry, 48, 915-921.
165. Solomon, D. A., Keitner, G. I., Miller, I. W., Shea, M. T., & Keller, M. B. (1995). Course of illness and maintenance treatments for patients with bipolar disorder. Journal of Clinical Psychiatry, 56, 5-13.
166. Song, F., Freemantle, N., & Sheldon, T. A. (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Journal of Medicine, 306, 683-687.
167. Sotsky, S. M., Glass, D. R., Shea, M. T., Pilkonis, P. A., Collins, J. F., Elkin, I., Watkins, J. T., Imber, S. D., Leber, W. R., Moyer, J., & Oliveri, M. E. (1991). Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry, 53, 283-290.
168. Souza, F. G. M., & Goodwin, G. M. (1991). Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. British Journal of Psychiatry, 158, 666-675.
169. Spanier, C., Frank, E., McEachran, A. B., Grochocinski, V. J., & Kupfer, D. J. (in press). The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: Integrating psychotherapeutic and biological factors. Psychological Medicine.
170. Spiker, D. G., & Kupfer, D. J. (1988). Placebo response rates in psychotic and nonpsychotic depression. Journal of Affective Disorders, 14, 21-23.
171. Spiker, D. G., Weiss, J. C., Dealy, R. S., Griffin, S. J., Hanin, I., Neil, J. F., Perel, J. M., Rossi, A. J., & Soloff, P. H. (1985). The pharmacological treatment of delusional depression. American Journal of Psychiatry, 142, 430-436.
172. Stewart, J. W., Mercier, M. A., Agosti, V., Guardino, M., & Quitkin, F. M. (1993). Imipramine is effective after unsuccessful cognitive therapy: Sequential use of cognitive therapy and imipramine in depressed outpatients. Journal of Clinical Psychopharmacology, 13, 114-119.
173. Stuppaeck, C. H., Geretsegger, C., Whitworth, A. B., Schubert, H., Platz, T., Konig, P., Hinterhuber, H., &. Fleischhacker, W. (1994). A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. Journal of Clinical Psychopharmacology, 14, 241-246.
174. Sunderland, T., Cohen, R. M., Molehan, S., Lawlor, B. A., Mellow, A. M., Newhouse, P. A., Tariot, P. N., Mueller, E. A., & Murphy, D. L. (1994). High-dose setegiline in treatment-resistant older depressive patients. Archives of General Psychiatry, 51, 607-615.
175. Suppes, T., McElroy, S. L., Gilbert, J., Dessain, E. C., & Cole, J. O. (1992). Clozapine in the treatment of dysphoric mania. Biological Psychiatry, 32, 270-280.
176. Taylor, D. P., Carter, R. B., Eison, A. S., Mullins, U. L., Smith, H. L., Torrente, J. R., Wright, R. N., & Yocca, F. D. (1995). Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Journal of Clinical Psychiatry, 56 (Suppl. 6), 3-11.
177. Teicher, M., Glod, C., & Cole, J. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
178. Thase, M. E. (1992). Long-term treatments of recurrent depressive disorders. Journal of Clinical Psychiatry, 53(Suppl.), 33-44.
179. Thase, M. E. (1993). Maintenance treatments of recurrent affective disorders. Current Opinion in Psychiatry 6, 16-21.
180. Thase, M. E. (1994). After the fall: Cognitive behavior therapy of depression in the "post-collaborattve" era. The Behavior Therapist, 17, 48-52.
181. Thase, M. E. (1995). Reeducative psychotherapy. In G. Gabbard (Ed.), Treatments of psychiatric disorders: DSM-IV edition (pp. 1169-1204). Washington, DC: American Psychiatric Press.
182. Thase, M. E., Bowler, K., & Harden, T. (1991). Cognitive behavior therapy of endogenous depression. Part 2: Preliminary findings in 16 unmedicated inpatients. Behavior Therapy, 22, 469-477.
183. Thase, M. E., & Howland, R. (1994). Refractory depression: Relevance of psychosocial factors and therapies. Psychiatric Annals, 24, 232-240.
184. Thase, M. E., Kupfer, D. J., & Jarrett, D. B. (1989). Treatment of imipramine-resistant recurrent depression. I. An open clinical trial of adjunctive I-triiodothyronine. Journal of Clinical Psychiatry, 50, 385-388.
185. Thase, M. E., Mallinger, A. G., McKnight, D., & Himmelhoch, J. M. (1992). Treatment of imipramine resistant recurrent depression: IV. A double-blind, crossover study of tranylcypromine in anergic bipolar depression. American Journal of Psychiatry, 149, 195-198.
186. Thase, M. E., & Rush, A. J. (1995). Treatment resistant depression. In F. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The fourth generation of progress (pp. 1081-1097). New York: Raven Press.
187. Thase, M. E., Simons, A. D., McGeary, J., Cahalane, J. F., Hughes, C., Harden, T., & Friedman, E. (1992). Relapse following cognitive behavior therapy of depression: Potential implications for longer-term forms of treatment? American Journal of Psychiatry, 149, 1046-1052.
188. Thase, M. E., Simons, A. D., & Reynolds, C. F., III. (1993). Psychobiological correlates of poor response to cognitive behavior therapy: Potential indications for antidepressant pnarmacotherapy. Psychopharmacology Bulletin, 29, 293-301.
189. Thase, M. E., Simons, A. D., & Reynolds, C. F., III. (1996). Significance of abnormal electroencephalographic sleep profiles in major depressions: Association with response to cognitive behavior therapy. Archives of General Psychiatry, 53, 99-108.
190. Thase, M. E., & Sullivan, L. R. (1995). Relapse and recurrence of depression: A practical approach for prevention. CNS Drugs, 4, 261-277.
191. Thase, M. E., Trivedi, M. H., & Rush, A. J. (1995), MAOls in the contemporary treatment of depression. Neuropsychopharmacology, 12, 185-219.
192. Thienhaus, O. S., Margletta, S., & Bennett, J. A. (1990). A study of the clinical efficacy of maintenance ECT. Journal of Clinical Psychiatry, 51, 141-144.
193. Tignol, J. (1993). A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. Journal of Clinical Psychopharmacology, 13(Suppl.), 18S-22S.
194. Toben, M., Castillo, J., Baldessarini, R. J., Zarate, C. & Kando, J. C. (1995). Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. American Journal of Psychiatry, 152, 413-418.
195. Vallejo, J., Gasto, C., Catalan, R., Salamero, M. (1987). Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. British Journal of Psychiatry, 151, 639-642.
196. Von Korff, M., Ormel, J., Katon, W., &. Lin, E. H. B. (1992). Disability and depression among high utilizers of health care. A longitudinal analysis. Archives of General Psychiatry, 49, 91-100.
197. Wachtel, H. (1990). The second messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry, 23, 27-32.
198. Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, A., Batey, S. R., &. Lineberry, C. G. (1993). Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Journal of Clinical Psychiatry, 54, 459-465.
199. Wehr, T. A., & Goodwin, F. K. (1987). Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry, 144, 1403-1411.
200. Weissman, M. M., Leaf, P. J., Bruce, M. L., & Florio, L. (1988). The epidemiology of dysthymia in five communities: Rates, risks, comorbidity, and treatment. American Journal of Psychiatry, 145, 815-819.
201. Wells, K. B., Katon, W., Rogers, B., & Camp, P. (1994). Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the medical outcomes study. American Journal of Psychiatry, 151, 694-700.
202. Wells, K. B., Stewart, A., Hays, R. D., Burnam, A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., & Ware, J. (1989). The functioning and well-being of depressed patients. Journal of the American Medical Association, 262, 914-919.
203. Whybrow, P. C., & Prange, A. J. (1981). A hypothesis of thyroid-catecholamine-receptor interaction: Its relevance to affective illness. Archives of General Psychiatry, 38, 106-113.
204. Winokur, G., Coryell, W., Keller; M., Endicott, J., & Akiskal, H. (1993). A Prospective follow-up of patients with bipolar and primary unipolar affective: disorder. Archives of General Psychiatry, 50, 457-465.
205. Zajecka, J. M., Jeffriess, H., & Fawcett, J. (1995). The efficacy of fluoxetine combined with a heterocyclic antidepressant ia treatment-resistant depression: A retrospective analysis: Journal of Clinical Psychiatry, 56, 338-343.
206. Zornberg, G. L., &. Pope, H. G. (1993). Treatment of depression in bipolar disorder: New directions for research. Journal of Clinical Psychopharmacology, 13, 397-408.